FMS-like tyrosine kinase 3 positive acute myeloid leukemia is a form of blood cancer where genetic changes in the FLT3 gene trigger uncontrolled growth of immature blood cells, creating challenges in treatment that researchers are working to overcome with new targeted therapies.

Epidemiology

FMS-like tyrosine kinase 3 positive acute myeloid leukemia, often referred to as FLT3-positive AML, affects a significant portion of people diagnosed with this blood cancer. Understanding how common these genetic changes are helps doctors and researchers develop better approaches to care.

Among adults newly diagnosed with acute myeloid leukemia (a cancer where the bone marrow makes too many immature blood cells that cannot function properly), approximately 30% carry mutations in the FLT3 gene. This makes FLT3 mutations one of the most frequently occurring genetic changes in this type of cancer.^[1][5] These mutations appear in people with otherwise normal chromosome structures, making genetic testing essential for proper diagnosis.

There are two main types of FLT3 mutations that doctors look for when testing patients. The more common type is called FLT3-ITD (internal tandem duplication), which occurs in about 25 to 30% of adult AML cases. The second type, known as FLT3-TKD (tyrosine kinase domain mutation), appears less frequently, affecting only 5 to 10% of AML patients.^[5][8] In rare situations, a small percentage of patients may have both types of mutations at the same time, which tends to lead to worse outcomes than having just one mutation.^[3]

The age range of patients affected by FLT3-positive AML typically includes younger and middle-aged adults, though the disease can occur at any age. Clinical trials examining treatments for this condition have often focused on patients between 18 and 59 years old, suggesting this represents a significant portion of those diagnosed with the mutation.^[3]

Causes

The root cause of FLT3-positive acute myeloid leukemia lies in changes to the genetic instructions that control how blood cells grow and develop. These genetic mutations create problems in the normal process of blood cell formation, leading to cancer.

The FLT3 gene normally provides instructions for making a protein called FMS-like tyrosine kinase 3 receptor, which sits on the surface of certain blood cells. This receptor belongs to a family of proteins called type III tyrosine kinases, which act like switches that control when cells should grow, divide, or mature into specialized cell types.^[3] In healthy bone marrow, this protein helps regulate the production and development of blood stem cells and early blood cell precursors.

When mutations occur in the FLT3 gene, the resulting protein becomes stuck in an “on” position, constantly sending growth signals even when they are not needed. The FLT3-ITD mutation involves a section of genetic code that duplicates itself and inserts back into the gene, creating an abnormally long protein. This duplicated section disrupts the normal shut-off mechanism of the receptor. The FLT3-TKD mutation, on the other hand, involves changes to specific building blocks in the part of the gene that controls enzyme activity.^[5][8]

These mutations cause the FLT3 receptor to activate continuously without needing its normal trigger. This constant activation switches on several downstream signaling pathways inside the cell, including STAT5-PIM and PI3K-AKT pathways, which normally regulate cell survival and multiplication.^[4] The overactive signals push immature blood cells to multiply rapidly while preventing them from maturing into functional blood cells. This creates a situation where the bone marrow fills with immature, non-functioning cells called blasts, which crowd out healthy blood cells.

FLT3 mutations can occur alongside other genetic changes in AML patients. These mutations often appear together with alterations in genes called NPM1, CEBPA, and various chromosomal abnormalities.^[3] The combination of different mutations can affect how aggressive the cancer becomes and how well it responds to treatment.

Risk Factors

Unlike some diseases where lifestyle choices or environmental exposures clearly increase risk, FLT3-positive AML develops from spontaneous genetic mutations that occur without obvious preventable causes. However, certain patterns have been observed in who develops these mutations.

The presence of other genetic mutations may create an environment where FLT3 mutations are more likely to occur or have greater impact. Patients with AML who have normal-appearing chromosomes under standard laboratory examination are particularly encouraged to undergo FLT3 testing, as these mutations are common in this group.^[3] This suggests that the absence of major chromosomal rearrangements may somehow relate to the development of FLT3 mutations.

Patients whose AML cells show other molecular mutations, particularly in the NPM1 gene, often also carry FLT3 mutations. While NPM1 mutations are generally considered a favorable prognostic factor when they occur alone, the presence of FLT3-ITD alongside NPM1 changes the outlook significantly, highlighting how these genetic factors interact.^[3]

Age appears to play some role in the development of FLT3-positive AML, with the condition affecting adults across a broad age range but showing particular relevance in younger to middle-aged adults. The disease can occur in older adults as well, though treatment approaches may differ based on a patient’s overall health and ability to tolerate intensive therapy.

There is no evidence that behavioral factors such as smoking, diet, or exercise directly influence whether someone develops FLT3 mutations in their AML. Similarly, the mutations are not contagious and cannot spread from one person to another like an infectious disease.

Symptoms

The symptoms of FLT3-positive acute myeloid leukemia stem from the accumulation of immature, non-functioning blood cells in the bone marrow and bloodstream. These abnormal cells crowd out healthy blood cells, leading to various problems throughout the body.

Patients may experience fatigue and weakness due to anemia, which occurs when there are not enough healthy red blood cells to carry oxygen to the body’s tissues. This shortage of oxygen-carrying cells can make even simple activities feel exhausting and may cause shortness of breath during normal movements.

The lack of functional white blood cells makes patients more vulnerable to infections. Because the bone marrow produces immature blasts instead of infection-fighting white blood cells, the body cannot properly defend itself against bacteria, viruses, and other microorganisms. Patients may develop frequent infections, fevers, or infections that do not improve with standard treatment.

Bleeding and bruising problems arise when the bone marrow cannot produce adequate platelets, the blood cells responsible for clotting. Patients might notice unusual bruising that appears without injury, small red spots on the skin called petechiae, bleeding gums, frequent nosebleeds, or heavy menstrual periods in women. Even minor cuts may take longer to stop bleeding than normal.

Some patients experience bone or joint pain as the expanding population of abnormal cells in the marrow creates pressure. Others may notice swollen lymph nodes, an enlarged spleen or liver, or a feeling of fullness in the abdomen. In some cases, leukemia cells can spread beyond the bone marrow and blood, affecting the gums, skin, or other organs.

Weight loss without trying, night sweats, and loss of appetite are common general symptoms that many cancer patients experience. These symptoms reflect the body’s response to the disease and the energy demands of rapidly dividing cancer cells.

FLT3-positive AML, particularly with the ITD mutation, is often associated with a high number of white blood cells circulating in the blood, though these cells are immature and cannot function properly.^[4] This high white blood cell count may not cause specific symptoms itself but indicates aggressive disease that requires prompt attention.

Prevention

Because FLT3-positive acute myeloid leukemia results from spontaneous genetic mutations that develop in blood cells during a person’s lifetime, there are no proven methods to prevent these mutations from occurring. The genetic changes happen within bone marrow cells without known external triggers that can be avoided.

Unlike some cancers where screening programs help detect disease early in people without symptoms, there is no routine screening test recommended for AML in the general population. The disease typically develops quickly, and its symptoms prompt medical evaluation, leading to diagnosis.

For patients already diagnosed with FLT3-positive AML, however, ongoing monitoring and appropriate treatment can help prevent complications and disease progression. Regular medical follow-up allows doctors to track how well treatment is working and detect any signs of the disease returning early, when intervention may be most effective.

Patients undergoing treatment for FLT3-positive AML should follow their healthcare team’s recommendations carefully, including taking medications exactly as prescribed, attending all scheduled appointments, and reporting any new or worsening symptoms promptly. This vigilance helps prevent complications and allows for timely adjustments to the treatment plan.

Some research has focused on maintenance therapy after initial treatment to prevent relapse. For example, studies have examined whether continuing FLT3 inhibitor medications after stem cell transplantation can reduce the risk of the disease returning.^[5] These maintenance strategies represent a form of secondary prevention, aimed at preventing recurrence in patients who have already had the disease.

Maintaining overall health through good nutrition, adequate rest, and infection prevention measures becomes particularly important for patients with FLT3-positive AML. While these measures do not prevent the development of the disease, they help patients better tolerate treatment and reduce the risk of complications during therapy.

Pathophysiology

The pathophysiology of FLT3-positive acute myeloid leukemia involves complex changes at the molecular and cellular level that transform normal blood cell development into a cancerous process. Understanding these mechanisms helps explain why the disease behaves as it does and guides treatment development.

In healthy bone marrow, the FLT3 receptor normally requires activation by a specific protein called FLT3 ligand to function. When this ligand attaches to the receptor, it causes two FLT3 receptors to pair together, triggering a cascade of chemical signals inside the cell. These signals are carefully controlled and tell blood stem cells when to divide, survive, or mature into specialized blood cell types.^[2]

When FLT3-ITD or FLT3-TKD mutations are present, the receptor no longer needs the ligand to become active. The FLT3-ITD mutation creates an abnormally long receptor that constantly pairs with itself and sends growth signals continuously. This constitutive activation means the receptor is always “turned on,” flooding the cell with signals to proliferate and survive, regardless of whether such growth is appropriate.^[4]

The constantly active FLT3 receptor triggers several important signaling pathways inside leukemia cells. One major pathway involves proteins called STAT5 and PIM, which promote cell survival and growth. Another involves the PI3K-AKT pathway, which prevents cells from dying and encourages them to multiply. These overlapping signals create a powerful push toward rapid cell division while simultaneously protecting cancer cells from the normal death processes that would eliminate abnormal cells.^[4]

Research has revealed additional complexity in how FLT3-ITD drives leukemia. The mutated FLT3 protein can recruit other cellular machinery to modify the genes that are turned on or off in leukemia cells. For instance, FLT3-ITD can recruit a protein called p300 to specific genes, which then adds chemical tags called acetyl groups to proteins that package DNA. These modifications make certain genes more accessible for activation, including CHK1, a gene involved in helping cells respond to DNA damage.^[4] This represents an epigenetic mechanism—a way of changing gene activity without altering the DNA sequence itself.

The activation of CHK1 by FLT3-ITD helps explain how leukemia cells cope with the stress created by their own rapid division. Fast-dividing cancer cells experience something called DNA replication stress, where the machinery copying DNA struggles to keep up with the demand. High levels of CHK1 help cancer cells manage this stress and avoid triggering cell death pathways that would normally eliminate cells with DNA problems.^[4]

The physical changes in the bone marrow reflect these molecular events. As FLT3-mutated leukemia cells multiply rapidly and fail to mature, they accumulate in the bone marrow, eventually making up a large percentage of the cells present. This crowding pushes out the space where normal blood cells would develop, leading to the decrease in healthy red blood cells, white blood cells, and platelets that causes many of the disease symptoms.

FLT3-ITD mutations also accelerate the cell division cycle, pushing cells through their growth and division phases more quickly than normal. The fusion protein encoded by the mutated gene has tyrosine kinase activity, meaning it can add phosphate groups to other proteins, which acts like flipping switches to activate numerous cellular processes simultaneously.^[4]

The differences between FLT3-ITD and FLT3-TKD mutations affect their clinical behavior. FLT3-ITD mutations are associated with higher risk of disease returning after treatment, shorter survival without disease progression, and reduced overall survival.^[3] FLT3-TKD mutations, occurring less frequently, generally do not carry the same level of prognostic significance, though they still represent targets for therapy.

Understanding these pathophysiological mechanisms has led to the development of drugs called tyrosine kinase inhibitors that specifically target the overactive FLT3 receptor. These medications work by blocking the enzymatic activity of the mutated FLT3 protein, thereby interrupting the excessive growth signals that drive leukemia cell proliferation. However, leukemia cells can develop resistance to these inhibitors through additional mutations or by activating alternative growth pathways, which remains an ongoing challenge in treatment.^[5][8]